Rapcabtagene AutoleucelPhase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06655896

Conditions

Scleroderma, Diffuse

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

rapcabtagene autoleucel

rituximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-08-19.